# Early-Phase IND Protocol Recommendations for Solid Tumors; Draft Guidance for Industry – FDA Guidance

Source: https://www.keypedia.com/guidances/guidance-document/early-phase-ind-protocol-recommendations-for-solid-tumors-draft-guidance-for-industry/8d88c301-3351-40b1-9d30-132f12e70b07

> FDA guidance document: Early-Phase IND Protocol Recommendations for Solid Tumors; Draft Guidance for Industry. Issue date: November 10, 2026. Get complete insights and analysis.

---

## Details

- Title: Early-Phase IND Protocol Recommendations for Solid Tumors; Draft Guidance for Industry
- Communication Type: Guidance Document
- Product Type: biologics
- Office Name: Office of the Commissioner
- Office URL: /offices/office-of-the-commissioner/79483979-9582-427f-ac3d-46c715811424
- Issue Date: 2026-11-10
- Comment Close Date: 2027-01-11
- Last Changed: 2026-11-10
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2026-D-13432">FDA-2026-D-13432</a>

## Related Documents

- [Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products: Draft Guidance](https://www.keypedia.com/guidances/guidance-document/oncology-pharmaceuticals-streamlined-nonclinical-safety-studies-for-biologics-and-conjugated-products-draft-guidance/c281f7a3-ef1f-4ee6-a357-dcddce26d99b)
- [Establishing Impurity Specifications for Antibiotics](https://www.keypedia.com/guidances/guidance-document/establishing-impurity-specifications-for-antibiotics/5bb8badb-7c32-4b76-bfc9-bbb8ab55fb84)
- [Tissue Agnostic Drug Development in Oncology: Draft Guidance for Industry](https://www.keypedia.com/guidances/guidance-document/tissue-agnostic-drug-development-in-oncology-draft-guidance-for-industry/3835823e-c995-46e5-98c7-9422ad94971f)